Xiaomei I Liu1, Paul Schuette2, Gilbert J Burckart3, Dionna J Green4, Julie La5, Janelle M Burnham6, Natella Rakhmanina1, Adelaide Robb1, Shiew Mei Huang6, John N van den Anker1. 1. Children's National Medical Center, Washington, DC. 2. Office of Biostatistics, United States Food and Drug Administration, Silver Spring, MD. 3. Office of Clinical Pharmacology, United States Food and Drug Administration, Silver Spring, MD. Electronic address: Gilbert.Burckart@fda.hhs.gov. 4. Office of Pediatric Therapeutics, United States Food and Drug Administration, Silver Spring, MD. 5. Loma Linda School of Pharmacy, Loma Linda, CA. 6. Office of Clinical Pharmacology, United States Food and Drug Administration, Silver Spring, MD.
Abstract
OBJECTIVE: To examine the differences in the adverse drug reaction (ADR) profile of antipsychotic and antidepressant agents between pediatric and adult patients in studies submitted to the Food and Drug Administration (FDA) during the drug development process. STUDY DESIGN: Clinical trials in adult and pediatric patients were conducted by sponsors as part of the drug development programs for antipsychotic and antidepressant agents, and ADR information was collected as part of those trials and submitted to the FDA. Data collection was conducted by reviewing publicly available FDA-authored reviews and FDA-approved product labels for 10 drugs with an antipsychotic or an antidepressant indication from 2007 to 2017. RESULTS: There were 308 drug and ADR combinations for the 10 drugs and drug combinations with 113 (36.7%) having a significantly different incidence in pediatric patients compared with adults. Sixty-eight (60.2%) of these ADRs had a significantly higher incidence in pediatric patients than in adults. Sedation was higher in 6 of the 10 drugs and drug combinations with risk differences ranging from 9.6 to 36.6%. CONCLUSIONS: This analysis indicates that there were significant differences between the pediatric and adult safety profiles of antipsychotic and antidepressant drugs. Sedation was the major ADR associated with the use of atypical antipsychotic drugs in pediatric patients. Clinicians caring for children should consider the ADR profile when prescribing antipsychotics and antidepressants in pediatric patients. Published by Elsevier Inc.
OBJECTIVE: To examine the differences in the adverse drug reaction (ADR) profile of antipsychotic and antidepressant agents between pediatric and adult patients in studies submitted to the Food and Drug Administration (FDA) during the drug development process. STUDY DESIGN: Clinical trials in adult and pediatric patients were conducted by sponsors as part of the drug development programs for antipsychotic and antidepressant agents, and ADR information was collected as part of those trials and submitted to the FDA. Data collection was conducted by reviewing publicly available FDA-authored reviews and FDA-approved product labels for 10 drugs with an antipsychotic or an antidepressant indication from 2007 to 2017. RESULTS: There were 308 drug and ADR combinations for the 10 drugs and drug combinations with 113 (36.7%) having a significantly different incidence in pediatric patients compared with adults. Sixty-eight (60.2%) of these ADRs had a significantly higher incidence in pediatric patients than in adults. Sedation was higher in 6 of the 10 drugs and drug combinations with risk differences ranging from 9.6 to 36.6%. CONCLUSIONS: This analysis indicates that there were significant differences between the pediatric and adult safety profiles of antipsychotic and antidepressant drugs. Sedation was the major ADR associated with the use of atypical antipsychotic drugs in pediatric patients. Clinicians caring for children should consider the ADR profile when prescribing antipsychotics and antidepressants in pediatric patients. Published by Elsevier Inc.
Entities:
Keywords:
US FDA; adverse drug effects; antidepressant; antipsychotic; drug development; pediatric; regulatory
Authors: Ruth Perou; Rebecca H Bitsko; Stephen J Blumberg; Patricia Pastor; Reem M Ghandour; Joseph C Gfroerer; Sarra L Hedden; Alex E Crosby; Susanna N Visser; Laura A Schieve; Sharyn E Parks; Jeffery E Hall; Debra Brody; Catherine M Simile; William W Thompson; Jon Baio; Shelli Avenevoli; Michael D Kogan; Larke N Huang Journal: MMWR Suppl Date: 2013-05-17
Authors: Jeremiah D Momper; Yang Chang; Matthew Jackson; Paul Schuette; Shirley Seo; Islam Younis; Darrell R Abernethy; Lynne Yao; Edmund V Capparelli; Gilbert J Burckart Journal: Ther Innov Regul Sci Date: 2015-03 Impact factor: 1.778
Authors: Marc Stone; Thomas Laughren; M Lisa Jones; Mark Levenson; P Chris Holland; Alice Hughes; Tarek A Hammad; Robert Temple; George Rochester Journal: BMJ Date: 2009-08-11
Authors: Jeffrey R Strawn; Scott T Aaronson; Ahmed Z Elmaadawi; G Randolph Schrodt; Richard C Holbert; Sarah Verdoliva; Karen Heart; Mark A Demitrack; Paul E Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2020-04-21 Impact factor: 2.576
Authors: R Taurines; S Fekete; A Preuss-Wiedenhoff; A Warnke; C Wewetzer; P Plener; R Burger; M Gerlach; M Romanos; K M Egberts Journal: J Neural Transm (Vienna) Date: 2022-03-18 Impact factor: 3.850
Authors: Anil R Maharaj; Huali Wu; Kanecia O Zimmerman; Julie Autmizguine; Rohit Kalra; Amira Al-Uzri; Catherine M T Sherwin; Stuart L Goldstein; Kevin Watt; Jinson Erinjeri; Elizabeth H Payne; Michael Cohen-Wolkowiez; Christoph P Hornik Journal: Br J Clin Pharmacol Date: 2020-07-05 Impact factor: 3.716
Authors: Xiaomei I Liu; André Dallmann; Yow-Ming Wang; Dionna J Green; Janelle M Burnham; Beatrice Chiang; Perry Wu; Mark Sheng; Kelley Lu; John N van den Anker; Gilbert J Burckart Journal: J Clin Pharmacol Date: 2019-03-13 Impact factor: 3.126
Authors: Lenneke Minjon; Ivona Brozina; Toine C G Egberts; Eibert R Heerdink; Els van den Ban Journal: Front Psychiatry Date: 2021-02-25 Impact factor: 4.157
Authors: Lenneke Minjon; Els van den Ban; Marloes T Bazelier; Arief Lalmohamed; Toine C G Egberts; Eibert R Heerdink Journal: J Child Adolesc Psychopharmacol Date: 2021-10-07 Impact factor: 2.576
Authors: Sanne Maartje Kloosterboer; Brenda C M de Winter; Catrien G Reichart; Mirjam E J Kouijzer; Matthias M J de Kroon; Emma van Daalen; Wietske A Ester; Rob Rieken; Gwen C Dieleman; Daphne van Altena; Beatrijs Bartelds; Ron H N van Schaik; Kazem Nasserinejad; Manon H J Hillegers; Teun van Gelder; Bram Dierckx; Birgit C P Koch Journal: Br J Clin Pharmacol Date: 2020-07-26 Impact factor: 3.716